STOCKS TELEGRAPH

Tag: CELZ stock

  • Creative Medical (CELZ) Shares Continued The Rally In After-Hour Trading

    Creative Medical (CELZ) Shares Continued The Rally In After-Hour Trading

    Investor excitement following encouraging clinical trial findings was reflected in the substantial increase in the stock price of Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) on Thursday. During regular trading, CELZ shares rose 11.14%, concluding at $4.59. After-hours trading saw an additional 8.93% increase, hitting $5.00.

    Promising Results for Type 2 Diabetes Therapy

    Creative Medical Technology released one-year follow-up data from its AlloStem (CELZ-201) pilot study, targeting late-stage Type 2 Diabetes patients. CELZ-201 is an allogenic, ready-to-use cell therapy designed to reduce insulin dependency and stabilize blood sugar levels. The study demonstrated an 80% overall efficacy rate in achieving these outcomes, with no reported serious adverse effects.

    The trial involved 20 participants, with 10 receiving the CELZ-201 infusion and 10 undergoing optimized medical therapy. Results confirmed the safety and effectiveness of the treatment, which utilizes the same infusion method currently being tested in the company’s FDA-approved Type 1 Diabetes clinical trial. The lack of safety issues emphasizes even more how promising CELZ-201 is as a ground-breaking diabetic therapy.

    Resolving a Pervasive Health Issue

    Type 2 diabetes, the seventh greatest cause of death in the US, affects 90–95% of the 38 million Americans and is a serious public health risk. More than 80% of the 96 million people who have prediabetes are not aware that they have the disease. Even though early-stage management involves lifestyle changes and oral medications, many patients eventually require insulin treatment as the diabetes worsens. 

    Future Growth and Innovation

    In light of these encouraging outcomes, Creative Medical Technology plans to investigate other therapeutic uses and expedite the development of AlloStem or CELZ-201 for advanced Type 2 Diabetes. The company’s diverse pipeline, which includes CELZ-201 for Type 1 diabetes in its early stages and CELZ-101 for brittle Type 1 diabetes, demonstrates its dedication to developing cutting-edge therapies that might fundamentally alter the way diabetes is managed.

  • Creative Medical Technology (CELZ) Stock Soars In Response To New Drug Clearance

    Creative Medical Technology (CELZ) Stock Soars In Response To New Drug Clearance

    Presently in the current trading session, Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is experiencing a notable surge, marking a 22.80% increase to $5.00 as per the latest update. This uptrend in CELZ stock correlates with the regulatory clearance obtained for a novel pharmaceutical product by the company.

    The U.S. Food and Drug Administration (FDA) has designated CELZ-101, often referred to as ImmCelz, as an orphan drug as publicly disclosed by Creative Medical Technology (CELZ). This innovative therapy aims to shield recipients of pancreatic islet cell transplants against allograft rejection.

    For people with fragile Type 1 diabetes, a condition characterized by erratic fluctuations in blood glucose levels, it is a significant breakthrough. CELZ-101, alternatively termed as Supercharged Treg Biologic Immunotherapy (ImmCelz), epitomizes a cutting-edge paradigm in personalized healthcare, leveraging the patient’s own regulatory T cells (Tregs) to counter autoimmune and alloimmune responses that may jeopardize insulin-producing cells.

    This groundbreaking therapy is rooted in a proprietary methodology not only amplifying Tregs but also augmenting their efficacy, promising a viable avenue to diminish the necessity for lifelong immunosuppressive measures. The conferment of Orphan Drug Designation by the FDA for CELZ-101 underscores the unwavering dedication of the company towards pioneering therapeutic modalities.

    This pivotal achievement catapults the endeavor closer towards offering a sustainable resolution for individuals contending with the persistent challenges of brittle Type 1 diabetes, hallmarked by erratic glycemic fluctuations. It is in consonance with CELZ’s overarching mission to enhance the quality of life for patients through the vanguard of regenerative medicine.

    The advancement of CELZ-101 marks a significant stride in the domain of cell-based immunotherapy, addressing the imperative requirement for more efficacious interventions in brittle Type 1 diabetes by striving for operational tolerance in islet cell transplantation, potentially liberating patients from the onus of lifelong immunosuppression.

    This heralds the debut of the first orphan-designated, synergistic cell-based immunotherapy for brittle Type 1 diabetes. The Orphan Drug Designation accorded by the FDA accentuates the potential of CELZ-101 in fulfilling a substantial unmet need in averting allograft rejection during pancreatic islet cell transplantation, which recently garnered FDA approval.

    This designation confers numerous consequential advantages to bolster the progression of the therapy including tax incentives, exemptions from user fees, and the prospect of market exclusivity post-approval.

  • Creative Medical Technology Holdings, Inc. (CELZ) stock gained 19.75% in after-hours. Why?

    Creative Medical Technology Holdings, Inc. (CELZ) stock gained 19.75% in after-hours. Why?

    The stock of Creative Medical Technology Holdings Inc (CELZ) closed the recent trading session at $1.57, gaining 5.37% from the previous trading session. During the last check, the stock of CELZ soared in the after-market, gaining 19.75%.

    CELZ News

    CELZ filed form 8-K with the SEC earlier this month to report the employment agreements. CEO and CFO entered into an agreement regarding the base salary, with the company. According to the agreement, the base salary of Mr. Timothy Warbington, CEO, remains $0.33 million per year. While the base salary of Mr. Donald Dickerson, CFO, remains $0.30 million annually. Further terms of the agreement are

    • The employment agreement is for three years.
    • Each executive can get a 30% cash bonus of their base salary, per year.
    • Every Executive is qualified for a yearly grant of a choice to buy various shares of normal stock of the Company with a worth of 30% of the Executive’s base compensation.
    • In case of termination, the executive will be qualified for the payment of base compensation and yearly rewards for two years.

    On December 3, 2021, CELZ also announced the public offering of its 3.8 million shares at the total cost of $16 million, at a price of $4.13 per share. Moreover,  the company said that it has now exhibited early achievement in animal models and at present has a forthcoming Investigational New Drug Application recorded with the FDA.

    About CELZ

    Creative Medical Technology Holdings, Inc (CELZ) is a biotech organization that is occupied with the advancement of urology, orthopedics, and nervous system science utilizing adult stem cell therapies. CELZ stock has a market cap of $21.38 million. CELZ is propelling the way that organizations address different immunity issues. Its ImmCelz stage is intended to “reinvent” immune cells in stroke patients. The company was founded in 1998 and has its base in Phoenix, Arizona, United States of America (USA).

    Conclusion

    The COVID-19 pandemic has prodded widespread development across the sub-sectors of the medical care industry for a while now, making this an appealing industry for investors. Things are working out positively for CELZ stock regardless of the shortfall of any stock news. It would be intriguing to perceive how lengthy this pattern will stay as the stock market is exceptionally eccentric.